ABSTRACT The demonstration is an effective initiative to bridge the gap between a premature technology and its large-scale commercialization. A systematic method of LCA was used to perform the well-to-wheel analysis of a CNG light-duty truck operated with 0%, 15%, and 30% blends of hydrogen with compressed natural gas fuel under the system boundary of “per vehicle km”. The GREET simulation was performed on GREET_1 (Excel Series_2017) to evaluate hydrogen production pathways with numerous parametric assumptions adopted to base the study in the context of China. Resource use, fossil energy use, GHG emission, and major air pollutants namely NOx and PM were studied. The idea was to demonstrate the effects of hydrogen addition throughout the entire fuel cycle of end-use of HCNG in an HCNG® LDV. The hydrogen blend of 30% with conventional CNG decreased the well-to-wheel GHG emission compared with 0%HCNG by 32.982%, 29.275%, and 9.694% with hydrogen pathways such as solar, biomass, and coke oven gas, respectively. Moreover, for 30%HCNG (Conv.NG), the well-to-wheel total energy consumption was increased by 15.176%, and 15.719% for solar and biomass-based pathways, respectively. However, although the energy consumption was increased for solar and biomass-based 15%HCNG and 30%HCNG pathways compared with 0%HCNG, the feedstock used was renewable and qualitatively cleaner. The worst scenario was found in the form of 30%HCNG (Conv.NG) with grid electrolysis pathway which showed 60.648% increment in WTW GHG and 75.479% increment in WTW total energy compared with baseline 0%HCNG (Conv.NG). The booming renewable electricity generation and availability of a tremendous amount of coke oven gas as by-products from coking industries in China can establish a prospective platform for sustainable hydrogen economy in China and is supposed to promote the commercialization of HCNG vehicles in future.

The degradation products of nonylphenol ethoxylates (NPnEO), nonylphenol (NP) and short-chain NPnEO are representative of environmental endocrine disruptors. They possess strong lipophilicity, toxicity, cumulative property and estrogenic effect. They can pollute the environment, cause body precocious, and induce the body's estrogen-sensitive cancer cell proliferation. A fast method using high performance liquid chromatography (HPLC) was developed to simultaneously quantify NP and 11 kinds of NPnEO in wastewater samples. The influence of mobile phase composition, mobile phase ratio, mobile phase flow rate, column temperature and sample injection volume on the separation effect was studied. Under the optimized conditions, NP and 11 kinds of NPnEO were separated successfully within 35 min. The method showed good linearity for NP and 11 kinds of NPnEO (n = 1-11). The linear correlation coefficients for the standard curves were 0.9720- 0.9999. The precision degree of the method was reliable and all the relative standard deviation (RSD) values (n = 0-11) obtained were less than 5.0%.

摘要 目的 评估抗逆转录病毒治疗（ART）早期进行磺胺甲基异恶唑预防疗法是否降低中国艾滋病病毒（HIV）感染成年人的死亡率。 方法 我们使用中国国家免费抗逆转录病毒数据库的数据进行回顾性观察性队列研究。对14岁以上在2010年1月1日至2012年12月31日之间开始ART治疗并且基...

Résumé Objectif Évaluer si la prophylaxie par le cotrimoxazole administrée précocement au cours de la thérapie antirétrovirale (TAR) réduit la mortalité chez les adultes infectés par le virus de l'immunodéficience humaine (VIH) en Chine. Méthodes Nous avons effectué une étude de cohorte par observation rétrospective en utilisant les données de la base de données antirétrovirale gratuite nationale chinoise. Les patients âgés de plus de 14 ans qui ont commencé une TAR entre le 1er janvier 2010 et le 31 décembre 2012 et qui avaient un nombre de lymphocytes T CD4+ (cellules CD4+) à la ligne de base inférieur à 200 cellules/µL, ont été suivis jusqu'à leur décès, jusqu'à ce qu'ils soient perdus de vue au suivi ou jusqu'au 31 ...

Резюме Цель Определить, приводит ли профилактика котримоксазолом на раннем этапе антиретровирусной терапии (АРТ) к снижению смертности среди ВИЧ-инфицирова...

Objective To assess if cotrimoxazole prophylaxis administered early during antiretroviral therapy (ART) reduces mortality in Chinese adults who are infected with human immunodeficiency virus (HIV). Methods We did a retrospective observational cohort study using data from the Chinese national free antiretroviral database. Patients older than 14 years who started ART between 1 January 2010 and 31 December 2012 and had baseline CD4+ T-lymphocyte (CD4+ cell) count less than 200 cells/µL were followed until death, loss to follow-up or 31 December 2013. Hazard ratios (HRs) for several variables were calculated using multivariate analyses. Findings The analysis involved 23 816 HIV-infected patients, 2706 of whom died during the follow-up. Mortality in patients who did and did not start cotrimoxazole during the first 6 months of ART was 5.3 and 7.0 per 100 person–years, respectively. Cotrimoxazole was associated with a 37% reduction in mortality (hazard ratio, HR: 0.63; 95% confidence interval, CI: 0.56–0.70). Cotrimoxazole in addition to ART reduced mortality significantly over follow-up lasting 6 months (HR: 0.65; 95% CI: 0.59–0.73), 12 months (HR: 0.58; 95% CI: 0.49–0.70), 18 months (HR: 0.49; 95% CI: 0.38–0.63) and 24 months (HR: 0.66; 95% CI: 0.48–0.90). The mortality reduction was evident in patients with baseline CD4+ cell counts less than 50 cells/µL (HR: 0.60; 95% CI: 0.54–0.67), 50–99 cells/µL (HR: 0.66; 95% CI: 0.56–0.78) and 100–199 cells/µL (HR: 0.78; 95% CI: 0.62–0.98). Conclusion Cotrimoxazole prophylaxis started early during ART reduced mortality and should be offered to HIV-infected patients in low- and middle-income countries.

ملخص الغرض تقييم ما إذا كانت الوقاية باستخدام الكوتريموكسازول في مرحلة مبكرة خلال العلاج بمضادات الفيروسات القهقرية يقلل معدل الوفيات بين البالغين المصابين ب...

Resumen Objetivo Evaluar si la profilaxis con cotrimoxazol en una etapa temprana de la terapia antirretroviral (TAR) reduce la mortalidad en adultos de origen chino infectados por el virus de la inmunodeficiencia humana (VIH). Métodos Se llevó a cabo un estudio de cohorte observacional retrospectivo utilizando los datos de la base de datos nacional de China de antirretrovirales de uso gratuito. Por otro lado, se realizó un seguimiento a pacientes mayores de 14 años que iniciaron el tratamiento con TAR entre el 1 de enero de 2010 y el 31 de diciembre de 2012 y con recuento basal de linfocitos T CD4+ (célula CD4+) inferior a 200 células/µl hasta su muerte, la pérdida de seguimiento o el 31 de diciembre de 2013. Se calcularon los cocientes de riesgos (CR) para diversas variables mediante análisis multivariados. Resultados En el análisis participaron 23 816 pacientes infectados por el VIH, 2706 de los cuales fallecieron durante el seguimiento. La mortalidad entre los pacientes que iniciaron y no iniciaron el tratamiento con cotrimoxazol durante los primeros 6 meses de la TAR fue de 5,3 y 7,0 por 100 personas/años, respectivamente. Cotrimoxazol se asoció a una reducción del 37 % en la mortalidad (cociente de riesgos, CR: 0,63, intervalo de confianza del 95 %, IC: 0,56 – 0,70). Además de la TAR, cotrimoxazol redujo la mortalidad considerablemente durante el seguimiento de 6 meses (CR: 0,65; IC del 95 %: 0,59 – 0,73), 12 meses (CR: 0,58; IC del 95 %: 0,49 – 0,70), 18 meses (CR: 0,49; IC del 95 %: 0,38 – 0,63) y 24 meses (CR: 0,66; IC del 95 %: 0,48 – 0,90). La reducción de la mortalidad resultó evidente en pacientes con recuento basal de células CD4+ inferior a 50 células/µl (CR: 0,60; IC del 95 %: 0,54 – 0,67), 50 – 99 células/µl (CR: 0,66; IC del 95 %: 0,56 – 0,78) y 100 – 199 células/µl (CR: 0,78; IC del 95 %: 0,62 – 0,98). Conclusión La profilaxis con cotrimoxazol iniciada en una etapa temprana de la TAR redujo la mortalidad y debe ofrecerse a los pacientes infectados por el VIH en países de ingresos bajos y medios.